MESOBLAST Aktie

 

Working with Parent Project Muscular Dystrophy and the Duchenne Registry on patient identification and trial awareness efforts ...

These shares are ending the week on a high. But why? The post Why Amaero, Mesoblast, Telix, and Tivan shares are charging higher today appeared first on The Motley Fool Australia....

Mesoblast outlines commercial strategy to double net revenues as Ryoncil® approaches US$100M net revenue milestone since launch last year...

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

Partnering with Parent Project Muscular Dystrophy to ensure timely access to the trial for eligible patients...

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

These shares are starting the week in the red. But why? The post Why Challenger, Lotus Resources, Mesoblast, and Wildcat shares are falling today appeared first on The Motley Fool Australia....

Mesoblast shares slip despite another strong quarterly sales update from Ryoncil. The post Mesoblast shares are back in the red on Tuesday. Here's why appeared first on The Motley Fool Australia....

Mesoblast shares are in focus as Ryoncil® delivers nearly US$100m in sales since launch, fueling future growth initiatives. The post Mesoblast shares: Ryoncil® underpins strong earnings growth appeared first on The Motley Fool Australia....

NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host its inaugural R&D Day on Wednesday, April 8, 2026 in New York City. The event will be webcast live from 8:00am to 11:00am EST and will include presentations from Mesoblast's senior leadership team and from key opinion leaders....

NEW YORK, March 11, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced the appointment of Teresa Montagut MD, PhD in the newly established position of Head of Clinical Development and Medical Affairs reporting to the Chief Medical Officer Dr. Eric Rose. In this role, Teresa will lead Mesoblast's medical affairs organization, fostering clinical collaborations and spearheading investigator-initiated trials, enhancing clinical and medical communications, and engaging with healthcare professionals. She will play a critical role in unlocking the value of Mesoblast's cell therapy programs in new pediatric and adult inflammatory conditions in partnership with investigators and key opinion leaders....

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

This biotech was up almost 9% before sinking into the red. The post What's going on with Mesoblast shares today? appeared first on The Motley Fool Australia....

Mesoblast posts strong H1 FY2026 results on the back of Ryoncil®'s US launch and robust revenue growth. The post Mesoblast shares: Revenue surges on Ryoncil® US launch in H1 FY2026 appeared first on The Motley Fool Australia....

NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operational highlights and financial results for the half year ended December 31, 2025....

NEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided data presented at the February 2026 Tandem Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for Blood and Marrow Transplant Research (CIBMTR) in Salt Lake City, Utah....

Bell Potter thinks this biotech could be cheap and heading much higher. The post Could Mesoblast shares hit $4.45 in 2026? appeared first on The Motley Fool Australia....

Mesoblast shares slip after its quarterly update, as investors focus on cash flow and execution. The post This ASX 200 stock just reported a milestone quarter. So why are its shares falling? appeared first on The Motley Fool Australia....

Mesoblast posts strong Ryoncil sales and secures new funding, with cash reserves set for upcoming clinical milestones. The post Mesoblast posts revenue jump and new funding: Key takeaways for investors appeared first on The Motley Fool Australia....

NEW YORK, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on use of Ryoncil® (remestemcel-L-rknd) since commercially available in March 2025 for the approved label in children 2 months and older with steroid-refractory acute graft-versus-host disease (SR-aGvHD). Ryoncil® is the first mesenchymal stromal cell (MSC) product approved by the U.S. Food & Drug Administration (FDA) for any indication.1...